Verastem Inc - Company Profile
Powered by 
All the sales intelligence you need on Verastem Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Verastem Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Verastem Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Verastem Inc (Verastem) is a late-stage development biopharmaceutical company that develops and commercializes new medicines to treat cancer. Its pipeline products include RAMP 301, RAMP 201 and IST-FRAME which treats recurrent/refractory low grade serous ovarian cancer; RAMP 203 targets recurrent or relapsed non-small cell lung cancer; RAMP 205 for pancreatic ductal adenocarcinoma; and IST for the treatment of gynecological cancers, mesonephric, recurrent or relapsed non-small cell lung cancer, colorectal cancer, and estrogen receptor-positive breast cancer. The company operates through its subsidiaries in the US and Germany. Verastem is headquartered in Needham, Massachusetts, the US.
Headquarters
United States of America
Address
Suite 500, 117 Kendrick Street, Needham, Massachusetts, 02494
Website
www.verastem.com
Telephone
1 781 2924200
No of Employees
102
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VSTM (NASD)
Revenue (2024)
$30.9M
209.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-60.3%
(2024 vs 2023)
Market Cap*
$698.2M
Net Profit Margin (2024)
XYZ
48.1%
(2024 vs 2023)
* As of and is in US$
Verastem Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Pipeline | Service: |
| Recurrent/Refractory Low Grade Serous Ovarian Cancer: | Investigator Sponsored Trials (ISTs) Program |
| RAMP 301 | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Verastem Inc | Merck & Co Inc | Pfizer Inc | AbbVie Inc | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
| City | Needham | Rahway | New York City | North Chicago | Cambridge |
| State/Province | Massachusetts | New Jersey | New York | Illinois | Cambridgeshire |
| No. of Employees | 102 | 75,000 | 75,000 | 57,000 | 96,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John Johnson | Chairman | Executive Board | 2025 | 67 |
| Daniel Paterson | Chief Executive Officer; Director; President | Executive Board | 2023 | 64 |
| Daniel Calkins | Chief Financial Officer | Senior Management | 2023 | - |
| John Hayslip , M.D | Chief Medical Officer | Senior Management | 2024 | - |
| Jonathan Pachter , PhD | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer